353227-95-9

Basic information

• Product Name: α-[(3,5-dimethoxyphenyl)methylene]-4-hydroxy-(αZ)-benzeneacetic acid
• Synonyms: α-[(3,5-dimethoxyphenyl)methylene]-4-hydroxy-(αZ)-benzeneacetic acid
• CAS NO: 353227-95-9
• Molecular Weight: 300.311
• Mol File: 353227-95-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: α-[(3,5-dimethoxyphenyl)methylene]-4-hydroxy-(αZ)-benzeneacetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: α-[(3,5-dimethoxyphenyl)methylene]-4-hydroxy-(αZ)-benzeneacetic acid(353227-95-9)
• EPA Substance Registry System: α-[(3,5-dimethoxyphenyl)methylene]-4-hydroxy-(αZ)-benzeneacetic acid(353227-95-9)

Safety Data

• Hazardous Substances Data: 353227-95-9(Hazardous Substances Data)

Upstream product

• 156-38-7 4-hydroxyphenylacetate 
• 918306-77-1 C₁₉H₁₈O₆ 
• 7311-34-4 3,5-dimethoxybenzaldehdye 
• 116518-98-0 E-3-(3,5-dimethoxy-phenyl)-2-(4-hydroxy-phenyl)-acrylic Acid 

Downstream Products

• 537-42-8 3,5-dimethoxy-4'-hydroxy-trans-stilbene 
• 1032508-01-2 (E)-O-4-(3,5-dimethoxystyryl)phenyl dimethylcarbamothioate 
• 1032508-02-3 (E)-S-4-(3,5-dimethoxystyryl)phenyl dimethylcarbamothioate 
• 1032508-00-1 trans-3',5'-dimethoxy-4-mercaptostilbene 
• 606932-85-8 (Z)-3-(3,5-dimethoxyphenyl)-2-(4-hydroxyphenyl)acrylic acid methyl ester 
• 606932-86-9 (Z)-3-(3,5-dimethoxyphenyl)-2-[4-(4-formylphenoxy)phenyl]acrylic acid methyl ester 

Relevant articles and documents

Synthesis and structure-activity relationship studies of cinnamic acid-based novel thiazolidinedione antihyperglycemic agents

A number of 2,4-thiazolidinedione derivatives of -phenyl substituted cinnamic acid were synthesized and studied for their PPAR agonist activity. The E-isomer of cinnamic acid, 11, showed moderate PPAR transactivation. The corresponding Z-isomer, 23, and d

Novel heterocyclic analogs of diphenylethylene compounds

Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.